which may be linked to the conjugation technology used in the drug and features as a black box warning on the product's label. The risk is said to be behind the somewhat slow take-up of Enhertu ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

US sales alone increased 35% year-on-year to ¥219.7 billion. The global product sales forecast for ENHERTU in FY2024 was revised upward to ¥539.9 billion, reflecting strong performance in HER2 ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu is fast becoming a major growth product for Daiichi Sankyo and AZ, with sales across the two companies reaching $1.77 billion in the first six months of the year, up from $1.16 billion in ...

has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending approval of Enhertu as a monotherapy for certain ...

Ongoing product governance issues (including litigation ... We have strong growth expectations for recently launched drugs Enhertu (HER2-expressing cancers, especially breast cancer), Truqap ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

This recommendation follows the positive results from the DESTINY-Breast06 phase 3 trial which demonstrated ENHERTU’s superiority over chemotherapy in terms of progression-free survival (PFS). The ...